We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

ANTIPARASITIC DRUGS MARKET ANALYSIS

Antiparasitic Drugs Market, By Product Type (Anthelmintics (Anticestodal Drugs, Antitrematodal Drugs, and Antinematodal Drugs) Antiprotozoal Agents (Antimalarials Agents Antibabesial Agents, Antiamoebic Agents, and Others (Trypanocidal Agents, Antileishmanial Agents, etc.)), Ectoparasiticide (Antiscabietic Agents and Pediculicides)), By Route Of Administration (Oral, Injectable, and Topical), By Application (Human Health, Animal Health, Crop Health) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

  • Published In : Jun 2023
  • Code : CMI3782
  • Pages :212
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Challenges And Opportunities

Global Antiparasitic Drugs Market: Restraints

Rising resistance to antimalarial drug regimens

On a global scale, parasite resistance to artemisinin has been identified in the Greater Mekong subregion and several areas in Africa– notably Eritrea, Rwanda and Uganda. While artemisinin resistance alone rarely leads to treatment failure, resistance to both artemisinin and the partner drug within act drug regimens can lead to high rates of treatment failure, as seen in recent years in parts of the Greater Mekong subregion.

Global Antiparasitic Drugs Market– Drivers

OIE (Office International des Epizooties) guide promotes responsible anthelmintic drug use

Guidance published by Office International des Epizooties in 2022 describes the dangers of resistance to deworming drugs and the ways people responsible for animal care can help preserve drug effectiveness.

Global Antiparasitic Drugs Market- Restraints

Rising resistance to antimalarial drug regimens

On a global scale, parasite resistance to artemisinin has been identified in the Greater Mekong subregion and several areas in Africa– notably Eritrea, Rwanda and Uganda. While artemisinin resistance alone rarely leads to treatment failure, resistance to both artemisinin and the partner drug within act drug regimens can lead to high rates of treatment failure, as seen in recent years in parts of the Greater Mekong subregion.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.